The Zhitong Finance App learned that Jinhai Medical Technology (02225) rose nearly 8% in early trading. As of press release, it rose 4.29% to HK$4.015, with a turnover of HK$4.447,600.

According to the news, in September of this year, at the “Frontier Design and Transformation of Implantable Interventional Medical Devices Forum”, Mr. Liu Lei, CEO of Shanghai Jinhai Medical Technology Co., Ltd., delivered a speech entitled “Intraoperative Approach and Visual Investigation and Accurate Positioning Imaging”, stating that companies must abandon impetuous parameter internal volumes and blind worship of pure patents to solidly polish the basic skills of optics and supply chains; in the future, AI, infrared, 3D imaging and intelligent navigation must be deeply integrated to enable minimally invasive endoscopy and accurate positioning imaging during surgery.

It is worth noting that on September 7, Jinhai Medical Technology was officially added to the Hong Kong Stock Connect list. This inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of share transactions. According to the data, Beishui Capital continued to increase its holdings in Jinhai Medical Technology. As of October 16, Hong Kong Stock Connect's shareholding ratio had increased to 0.86%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.